Nkarta Inc (NKTX) Actualités

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three...

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Nkarta to Participate in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a...

Form 4 - Statement of changes in beneficial ownership of securities

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report